Revenue surge masks PAT decline; integration ongoing, base business resilient

Delivered 4979 Cr, +50.8% YoY — matches

Delivered OPM 33.3% — within rounding

Prior guidance was high single-digit to low double-digit growth; -7% misses it

Specific segment claim; overall India branded grew 7% post-integration

Prior guidance '>₹100 Cr'; call signals acceleration but no new numeric target

Guidance is directional; no specific FY27 margin target restated

From 3 years to 2 years; tracking higher than ₹100 Cr initial guidance. ~₹450 Cr estimated, roughly half in FY27. Faster realization is positive but deferred specificity on full quantum.

Q2 growth only 7% (vs 20% base business growth) due to JB integration; H2 expected 'perhaps higher than 10%'. Management expects recovery but execution risk remains.

Q2 EBITDA margin 33.3% (vs Q1 33.5% implied); prior guidance was 0.5% annual improvement. H2 expected to improve but quantification withheld. R&D spend increased to 4.2% (vs 3.5% Q1) as temporary investment.

Guidance still withdrawn, but call provides recovery color: supply restored by Sep, market size ~₹800 Cr, company at 32% share. Stabilization expected but market size is early estimate.

Q2 at 7%, Q1 at 13%. Expect gradual recovery; H2 total JB growth should recover to double-digit. Integration transient, actions being taken.

Tracking higher than initial ₹100 Cr guidance. Possibly ₹450 Cr by next year. Most could come through by next year; in 2 years instead of 3. No further upside detail given.

Yes, that's fair assumption. JB base business EBITDA margins improving, directional improvement expected for next 2-3 quarters. Exact sequential improvement not guided.

Temporary for 2-3 years; range 4% to 4.5% in coming year. Intended to recover filings in US and increase productivity in expanded divisions.

Brazil optimistic for double-digit mid-teens growth; 53 products in ANVISA review. GLP-1 generic launch by local large player in last 3 months; Torrent expects launch in next 6-9 months.

Filings improved; 4 products filed YTD, expect 4-5 more before FY end. Market shares above expectations. Pricing pressure expected in H2; new launches should keep growth positive. Volume and new products offsetting price erosion.

Market size ~₹800 Cr for first year. Post-Sitagliptin pattern expected: high growth early years, stabilization by year 3-4. 2-2.5 Cr market possible after 3-4 years. On-track to recover.

H1 market growth 12% (above historical trend). Expect this to sustain or drop slightly to 10-11%. Minimum 10% growth expected; higher growth temporary due to semaglutide and field force expansion.

Across geographies due to integration (software, accounting, quality systems). US product recall also occurred. Not localized to one region; back-office integration issues.

Multiple factors: semaglutide launch, field force expansion, base business growth unchanged. Trade generics stable; branded segment growing. Hard to pinpoint exact driver; likely combination of all.

Brand extensions in OTC space launched; not major standalone launches yet. Idea is multiple small launches scaling up over 2-3 years to create sizable base.

Unclear durability in off-patent generics; competitive advantage depends on competitor entry speed. Constantly improving costs; price and volume dynamics neutralize each other. Maintaining share is the goal, not price premium.

No FY28 guidance yet. Waiting for full-year base to come in; Q1 FY28 will provide FY28 guidance.

Aman Mehta: H1 at 10%, H2 expected higher. Total JB growth to recover to double-digit in H2. Integration impact transient.

Sanjay Gupta: Optimistic on momentum from new launches and other businesses; 4 units performing well

4 products filed YTD, 4-5 more expected before FY end. Market shares above expectations; launches driving growth

Sudhir Menon: Gradual increase expected; Q3-Q4 to improve modestly. JB EBITDA margins improving sequentially.

No specific FY27 or FY28 margin targets given; directional improvement expected as integration benefits accrue

India branded growth slowed to 7% (vs 20% base business); integration ongoing, margin recovery dependent on execution. Timeline for full synergy realization unclear.

International segment down 7% YoY, missing prior guidance of high single-digit to low double-digit growth. JB international particularly impacted by integration, but recovery timeline uncertain.

Net profit down 9.6% YoY despite 50.8% revenue growth and 54% EBITDA growth. Suggests integration costs, R&D spend increase (4.2% vs 3.5%), and operating leverage challenges. Bottom-line compression not adequately explained.

Semaglutide guidance was withdrawn prior call pending recovery trajectory. While call provides recovery narrative (₹800 Cr year-1 market size estimate, 32% share), actual market size and durability are uncertain. New manufacturing partner onboarded, but supply/demand balance not quantified.

Sanjay Gupta acknowledges new competitors entering on recent launches; pricing pressure expected in H2. Off-patent generics have flat base fundamentals with price/volume tradeoffs; no durable competitive advantage in mature molecules.

Germany revenue down 13% constant currency YoY. Management attributes to supply-related issues and government-mandated price decreases. Stabilization expected but timeline uncertain (3-4 quarters suggested).